FLAG Therapeutics
FLAG Therapeutics is a near-term clinical stage company focused on developing new small molecule therapeutics for difficult-to-treat cancers. Their pipeline includes investigational therapeutics for gliomas, ovarian cancer, mesothelioma, pancreatic cancer, and other cancers, leveraging proprietary drug discovery platforms. The company aims to provide innovative treatment options for unmet medical needs in oncology.
Industries
Nr. of Employees
small (1-50)
FLAG Therapeutics
Products
Lead multi-target small-molecule candidate for CNS gliomas (anti-angiogenic and tubulin inhibition)
A water‑soluble, low-molecular-weight investigational small molecule designed to inhibit tumor angiogenesis via multiple receptor targets and disrupt tubulin function; demonstrated BBB penetration and P-gp evasion in preclinical studies and advanced toward IND/Phase 1 planning for diffuse intrinsic pontine glioma and glioblastoma.
Antifolate small-molecule candidates targeting FR-α and GARFTase for ovarian cancer and mesothelioma
Water-soluble antifolate compounds designed for selective uptake by folate receptor–expressing tumors and inhibition of GARFTase to disrupt purine synthesis; preclinical models reported high response rates and orphan designation eligibility/grant status for certain indications.
Antifolate small-molecule candidates targeting SHMT2 / one‑carbon metabolism for pancreatic cancer
Small molecules designed to inhibit cytosolic and mitochondrial one‑carbon metabolism enzymes (e.g., SHMT2) as a therapeutic approach for pancreatic cancer and related indications.
Lead multi-target small-molecule candidate for CNS gliomas (anti-angiogenic and tubulin inhibition)
A water‑soluble, low-molecular-weight investigational small molecule designed to inhibit tumor angiogenesis via multiple receptor targets and disrupt tubulin function; demonstrated BBB penetration and P-gp evasion in preclinical studies and advanced toward IND/Phase 1 planning for diffuse intrinsic pontine glioma and glioblastoma.
Antifolate small-molecule candidates targeting FR-α and GARFTase for ovarian cancer and mesothelioma
Water-soluble antifolate compounds designed for selective uptake by folate receptor–expressing tumors and inhibition of GARFTase to disrupt purine synthesis; preclinical models reported high response rates and orphan designation eligibility/grant status for certain indications.
Antifolate small-molecule candidates targeting SHMT2 / one‑carbon metabolism for pancreatic cancer
Small molecules designed to inhibit cytosolic and mitochondrial one‑carbon metabolism enzymes (e.g., SHMT2) as a therapeutic approach for pancreatic cancer and related indications.
Services
Management and provision of exclusive worldwide licensing rights and sublicensing options for small-molecule discovery platforms originating from a university research laboratory.
Management and provision of exclusive worldwide licensing rights and sublicensing options for small-molecule discovery platforms originating from a university research laboratory.
Expertise Areas
- Small-molecule drug discovery
- Medicinal chemistry and SAR
- Multi-target oncology therapeutics
- Preclinical pharmacology and in vivo efficacy
Key Technologies
- Small-molecule medicinal chemistry
- Multi-target receptor tyrosine kinase inhibition
- Tubulin/microtubule inhibition
- Antifolate enzyme inhibition (GARFTase, SHMT2)
News & Updates
July 16, 2024. The company announced positive preclinical data for FLAG-003, a candidate for DIPG.
July 1, 2024. The company presented a poster demonstrating FLAG-003 activity against DIPG.
FLAG-003 received Orphan Drug Designation in the US and EU for Glioma.
FLAG-003 received RPD designation for DIPG.
July 16, 2024. The company announced positive preclinical data for FLAG-003, a candidate for DIPG.
July 1, 2024. The company presented a poster demonstrating FLAG-003 activity against DIPG.
FLAG-003 received Orphan Drug Designation in the US and EU for Glioma.
FLAG-003 received RPD designation for DIPG.